Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
The current Regeneron(REGN) stock price is $732.46, with a market capitalization of 75.41B. The stock trades at a price-to-earnings (P/E) ratio of 17.95 and offers a dividend yield of 0.51%.
During the trading session on 2026-10-06, Regeneron(REGN) shares reached a daily high of $734.97 and a low of $721.96. At a current price of $732.46, the stock is +1.5% higher than the low and still -0.3% under the high.
Trading volume for Regeneron(REGN) stock has reached 37.81K, versus its average volume of 769.46K.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $541.00.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $541.00.
REGN News
The latest announcement is out from Regeneron ( (REGN) ). On October 1, 2026, Regeneron and long-time partner Sanofi expanded their antibody collaboration thro...
JPMorgan raised the firm’s price target on Regeneron (REGN) to $950 from $900 and keeps an Overweight rating on the shares ahead of the Q3 report. The firm expe...
...
Analyst ratings
63%
of 30 ratingsMore REGN News
Regeneron Pharmaceuticals reported early ubamatamab data in recurrent low-grade serous ovarian cancer and Phase 2 trevogrumab results in GLP-1 weight loss thera...
Regeneron Pharmaceuticals (REGN) just expanded its long-running immunology alliance with Sanofi, securing a US$1b upfront payment and potential milestones up to...
Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi and Regeneron have completed a new real-world stud...
Regeneron (REGN) Pharmaceuticals announced the first results for the investigational ubamatamab in patients with low-grade serous ovarian cancer. The data are f...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) are expanding their extensive, two-decade-long antibody partnership to jointly develop a...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-ac...
A prior litigation related to the collaboration was settled as part of the agreement, the companies said. Sylvain Thomas / Agence France-Presse / Getty Images...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.